|
|
|
|
|
|
|
|
|
|
MedNews
May 23, 2013 -- Soricimed Biopharma Inc., a private clinical stage company developing novel cancer therapeutics and diagnostics, is pleased to announce that it has added a third site and first U.S. site, to its Phase I clinical trial, with the first patient beginning treatment this week with anti-cancer agent SOR-C13 at The University of Texas MD Anderson Cancer Center in Houston, Texas.
Soricimed’s Phase I trial is a multicenter, open-label, dose escalation study that is taking place at cancer centres in both the United States and Canada. The trial is designed to assess safety and tolerability in patients with advanced cancer tumors, with a weighting on ovarian cancers. The trial will also assess pharmacokinetics, biomarkers and initial evidence for efficacy.......
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.